This is a rare type of cancer that starts in the ovary. It's thought to come from early egg cells. It's often found in young women and is usually treated with surgery.
Every report comes from a Lived member, sent anonymously.
Have you had Salpingo-oophorectomy for Dysgerminoma?
Dysgerminoma is a cancer that starts in the germ cells of the ovary, the cells that would normally develop into eggs. It is the most common type of malignant ovarian germ cell tumor, a group of ovarian cancers that differs in important ways from the more familiar ovarian cancers of older women. Dysgerminoma mostly affects teenagers and young women, usually forms in just one ovary, and is often found while it is still confined there. The tumor can grow quickly and become large, which is why it often shows up as a swollen abdomen or a mass someone can feel, sometimes with pain. Despite that, it is one of the most treatable cancers of the ovary. It responds very well to treatment, and most people are cured, often with surgery that leaves the uterus and the other ovary in place. Under the microscope it looks the same as seminoma, a testicular cancer, and the two respond to treatment in similar ways.
In most people, no cause is found. Researchers think dysgerminoma develops from early germ cells that did not mature normally, likely through a mix of genetic and other factors. Nothing a person did or did not do is known to cause it. One clearly recognized risk is a difference in sex development called XY gonadal dysgenesis, such as Swyer syndrome. People with this condition have a female body and XY chromosomes, and their underdeveloped gonads have a high chance of forming a tumor. It often comes to light when periods do not start by the expected age. Finding it early allows doctors to recommend removing the gonads before a cancer can develop, which is why missing periods in a teenager deserve a full medical evaluation rather than hormone treatment alone.
Dysgerminoma is usually first suspected when an exam or an ultrasound shows a solid mass on an ovary. A pelvic ultrasound, often done through the vagina, shows the size and structure of the mass, and a CT or MRI scan of the abdomen and pelvis helps show whether it has spread to lymph nodes or other organs. Blood tests called tumor markers, substances some tumors release into the blood, can point toward a germ cell tumor. Dysgerminoma often raises lactate dehydrogenase (LDH), an enzyme, and sometimes human chorionic gonadotropin (hCG), the hormone measured in pregnancy tests, which can make a pregnancy test read positive. No marker is specific enough to diagnose dysgerminoma on its own, but markers that are raised at diagnosis are useful for tracking treatment and spotting a return. The diagnosis is confirmed when a pathologist examines the removed tumor. During the operation, the surgeon also checks the abdomen, the other ovary and nearby lymph nodes and takes samples to determine the stage, from stage I (limited to one or both ovaries) to stage IV (spread to distant organs). The stage is the main factor in deciding whether more treatment is needed.
Surgery is the first and often the only treatment. For a young person with a tumor limited to one ovary, the usual operation removes that ovary and its fallopian tube while keeping the uterus and the other ovary, which preserves the chance of periods and pregnancy later. The exception is dysgerminoma arising in XY gonadal dysgenesis: both gonads are usually removed, because the other one carries a high cancer risk and does not produce eggs, but the uterus can be kept, which leaves pregnancy with donor eggs possible. Because dysgerminoma involves both ovaries in about 1 in 10 cases, the surgeon examines the other ovary carefully. For people who have finished having children, or after menopause, removing the uterus and both ovaries is more common. Care at a center experienced in gynecologic cancers helps ensure the surgery and staging are done fully. What happens after surgery depends on the stage. When the tumor was confined to one ovary and staging was complete (stage IA), many people need no further treatment and are followed with regular checkups instead. Roughly 15% to 25% of them later have a recurrence, but because dysgerminoma responds so well to chemotherapy, a recurrence found on follow-up can usually still be cured. This approach spares most people chemotherapy they would not have needed. For more advanced or incompletely removed disease, chemotherapy is given after surgery. The standard combination is BEP: bleomycin, etoposide and cisplatin, given in cycles about three weeks apart. Some people receive carboplatin with etoposide instead, a gentler combination that has worked well for dysgerminoma. Chemotherapy is highly effective here, even when tumor remains after surgery. Its trade-offs build up with the number of cycles: bleomycin can scar the lungs, cisplatin can affect the kidneys and hearing, and etoposide carries a small risk of a later blood cancer. That is why doctors match the amount of treatment to the risk rather than giving chemotherapy to everyone. Radiation also works against dysgerminoma but is now rarely used, mainly because it usually causes loss of ovarian function and fertility. If chemotherapy is planned, it is worth discussing fertility preservation beforehand. Options include freezing eggs, embryos or ovarian tissue, and medicines that temporarily quiet the ovaries during treatment (gonadotropin-releasing hormone, or GnRH, agonists), although how much these help in this specific cancer is not well established.
The outlook for dysgerminoma is very good. In United States cancer registry data, about 97% of people had not died of the cancer five years after diagnosis, the best outcome among ovarian germ cell tumors. Results are less favorable when the cancer has spread widely at diagnosis or when it occurs after about age 40, and tumors mixed with other germ cell types behave differently. After surgery alone, most people recover over several weeks and return to school, work and normal activity. Chemotherapy typically lasts a few months and brings fatigue, nausea and a temporary drop in blood counts, and it can interrupt periods. Many people who keep one ovary go on to have regular periods and some have pregnancies, but fertility is not guaranteed, particularly after chemotherapy. Follow-up is a long-term part of care. A common schedule involves exams and blood tests (including any tumor markers that were raised) every few months in the first two years, then less often until five years and yearly after that, with periodic ultrasound or CT scans. Survivors treated with chemotherapy should also have their blood pressure and hearing checked over time, since long-term effects such as high blood pressure, ringing in the ears and hearing loss are more common after this treatment.
See a clinician if you notice a swollen abdomen without weight gain elsewhere, a lump or fullness in the lower abdomen, or ongoing pelvic pain, and arrange an evaluation for a teenager whose periods have not started by the expected age. After treatment, contact your care team if abdominal swelling, a lump or persistent pelvic pain returns between follow-up visits rather than waiting for the next scheduled check. Sudden, severe pain in the lower abdomen or pelvis in someone with a known or suspected ovarian mass needs emergency care right away, because a large ovarian tumor can twist or rupture.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Dysgerminoma is like, what's helped you, or ask the community a question.